What It Is
Low-dose testosterone therapy for women is used off-label for hypoactive sexual desire disorder (HSDD) - clinically significant low sexual desire causing personal distress, after other causes have been ruled out. There is no FDA-approved testosterone product specifically indicated for women in the United States. All testosterone prescribed for women is either compounded or used off-label from male-indicated products at reduced doses.
The 2019 Global Consensus Statement on testosterone therapy for women - endorsed by multiple international societies including the International Society for the Study of Women’s Sexual Health (ISSWSH) - supports testosterone therapy specifically for HSDD in postmenopausal women, and only after other contributing factors have been addressed.
What It Is NOT For
Testosterone is not a general wellness hormone for women. It is not FDA-approved for fatigue, cognitive function, mood, bone density, or general quality of life in women. Some clinics market testosterone as part of a “hormonal optimization” package for women. The evidence does not support this broad application. The professional consensus supports testosterone therapy for one specific indication: HSDD in postmenopausal women.
Who It Is For
Postmenopausal women with clinically diagnosed HSDD who are already on estrogen therapy, have had other causes of low desire evaluated and addressed (relationship factors, medications, depression, fatigue, pain with intercourse from GSM), and have discussed the off-label nature and limited long-term safety data with their clinician.
Practical Considerations
Dosing is approximately one tenth of male testosterone doses. Compounded topical cream is the most common formulation. Monitoring testosterone levels is essential to keep levels within the female physiologic range. Levels should be checked at 3 to 6 week intervals initially, then periodically.
Side effects of excess dosing include acne, facial/body hair growth (hirsutism), voice deepening, and clitoral enlargement. Some androgenic effects (particularly voice changes) may be irreversible. This is why careful dosing and monitoring matter.
The Evidence Limitation
Long-term safety data for testosterone in women beyond 2 years is lacking. The Global Consensus Statement explicitly notes this limitation and recommends regular reassessment of the need for continued therapy. If testosterone has not improved HSDD symptoms after 6 months of adequate dosing, it should be discontinued.
Cost
Compounded topical testosterone: $30 to 100 per month. Not covered by insurance. Some clinics bundle testosterone with estrogen therapy at a combined price.
Questions To Ask
- Have we ruled out other causes of low desire before considering testosterone?
- What is the target testosterone level, and how will you monitor it?
- What side effects should I watch for, and which are reversible versus irreversible?
- What is the evidence for testosterone for my specific concern?
- How long should I trial testosterone before deciding whether it is working?
- If you prescribe testosterone for indications beyond HSDD, what evidence supports that?